Combating 2019-nCoV: Advanced Nanobiosensing platforms for POC global diagnostics and surveillance

Grant number: 101003544

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $2,903,753.28
  • Funder

    European Commission
  • Principal Investigator

    LECHUGA Laura
  • Research Location

    Spain
  • Lead Research Institution

    FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The recent outbreak in China caused by the emerging nCoV virus is challenging the level of global readiness from governments, public organizations and community to face and manage both its social and health consequences. Once the emergence is recognized and identified, it is crucial to initiate the necessary measures to prevent the spread. This involves therapeutics, vaccines, and devising efficient, fast, readily accessible diagnostics methods that specifically confirm the presence of the virus. Early detection can allow the rapid implementation of containment measures, which are the key to reduce the risk of amplification. The aim of CoNVat is to implement a Point-of-care label free biosensor for the direct, fast and specific identification of nCoV in decentralized settings to improve its early diagnosis and the clinical management of patients. The approach employs an already developed technology based on nanophotonic bimodal waveguide (BiMW) interferometers capable of providing real time, highly sensitive detections assays in short sample turnaround times. We propose two different strategies: (i) the development of a fast antigen-based diagnostic test for the specific detection of the intact virus in patient'Äôs samples such as respiratory specimens and non-respiratory fluids (serum, urine'Ķ) to be deployed to clinical settings for initial screening and (ii) development of a multiplexed molecular test, PCR-free, for the reliable identification of nCoV, being possible to differentiate the type and strain of coronavirus form other related or more common respiratory viruses. This latter strategy will provide a disruptive diagnostic tool not only from a clinical perspective to improve patient'Äôs outcome but also for surveillance, to study and understand possible transmission routes of this virus by analysing samples from animal reservoirs. Final prototype validation will demonstrate the potential of this approach for the management of future infectious outbreaks.

Publicationslinked via Europe PMC

Last Updated:43 minutes ago

View all publications at Europe PMC

Comparison of SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples from Patients Infected with Omicron Variant.

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation.

SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus.

Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics?

Engineering photonics solutions for COVID-19.

How Nanophotonic Label-Free Biosensors Can Contribute to Rapid and Massive Diagnostics of Respiratory Virus Infections: COVID-19 Case.

Development and Evaluation of a duo SARS-CoV-2 RT-qPCR Assay Combining Two Assays Approved by the World Health Organization Targeting the Envelope and the RNA-Dependant RNA Polymerase (RdRp) Coding Regions.

Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples.